New cell therapy trial offers hope for Tough-to-Treat lung cancer
Disease control
Recruiting now
This early-stage study is testing a new combination treatment for advanced non-small cell lung cancer (NSCLC) that has come back or stopped responding to standard therapies. It combines an experimental cell therapy called NK510 with existing PD-1 inhibitor drugs. The study will e…
Phase: EARLY_PHASE1 • Sponsor: Base Therapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC